CVS Health Corporation (CVS)
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Stocks in the S&P 500 Index Have Done the Unthinkable and Rocketed at Least 45% This Year Despite Trump's Tariffs
President Donald Trump's first 100 days proved tumultuous for the stock market. Trump instituted tariffs in his bid to bring more manufacturing jobs back to the U.S. and shake up global trade.
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone
Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly's obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to CVS's exclusion, creating a temporary mispricing in Lilly's stock, presenting a potential buying opportunity. Despite CVS's exclusion, Zepbound still has broad market access through other PBMs and regional health plans, ensuring continued sales growth.
CVS Health: Why I'm Not Buying The Post-Earnings Share Buoyancy
CVS Health Corporation's Q1 2025 earnings show strong growth, with revenues up 7% YoY and adjusted EPS up 72%, but caution is advised for the long-term outlook. Despite positive quarterly results, CVS downgraded its full-year 2025 revenue guidance and faces ongoing challenges in its Medicare Advantage business. CVS is addressing issues in its Health Care Benefits division by terminating unprofitable contracts and improving star ratings, but risks remain high.
CVS Health (CVS) Q1 2025 Earnings Call Transcript
CVS Health Corporation (NYSE:CVS ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial Officer Prem Shah - Group President, CVS Health Steve Nelson - President, Aetna Larry McGrath - Chief Strategy Officer, Investor Relations Conference Call Participants Justin Lake - Wolfe Research Lisa Gill - JP Morgan Stephen Baxter - Wells Fargo Elizabeth Anderson - Evercore ISI Andrew Mok - Barclays Michael Cherny - Leerink Partners Charles Rhyee - TD Cowen Ann Hynes - Mizuho Securities Operator Good morning and thank you all for attending the CVS Health first Q1 2025 earnings call. My name is Bricka and I'll be your moderator for today.
CVS Health raises full-year profit outlook as Q1 earnings top estimates
CVS Health Corp (NYSE:CVS) shares rose after the pharmacy chain raised its full-year profit guidance and delivered strong financial results for the first quarter. The company now expects 2025 adjusted earnings per share (EPS) in the range of $6 to $6.20, up from its earlier guidance of $5.75 to $6.
Compared to Estimates, CVS Health (CVS) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for CVS Health (CVS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
CVS Health Stock Surges as Q1 Results Handily Top Estimates
CVS Health (CVS) shares powered 9% higher before the bell Thursday after the pharmacy and healthcare giant's first-quarter results handily topped estimates.
CVS Health (CVS) Q1 Earnings and Revenues Beat Estimates
CVS Health (CVS) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.31 per share a year ago.
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Under a new partnership between Caremark and Wegovy's manufacturer, Novo Nordisk, CVS will make the drug available to its members at "a more affordable price.
